Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Surfactant Clear all
Suspended Phase 2 Interventional

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

NCT04056741
View directory record Official record
Conditions
RDS of Prematurity, Surfactant Protein B Deficiency, Chronic Lung Disease
Interventions
surfactant airway device
Combination Product
Lead sponsor
ONY
Industry
Eligibility
24 Weeks and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
San Diego, California • St. Petersburg, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation

NCT01042600
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal tube insertion, Laryngeal mask airway insertion
Device
Lead sponsor
Albany Medical College
Other
Eligibility
4 Hours to 48 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Jul 22, 2026, 2:20 PM EDT
Recruiting Not applicable Interventional

Video vs. Direct Laryngoscopy for Less Invasive Surfactant Administration

NCT07426016
View directory record Official record
Conditions
Respiratory Distress Syndrome (Neonatal), Surfactant Deficiency Syndrome Neonatal
Interventions
Video Laryngoscopy, Direct Laryngoscopy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 3 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Not listed Phase 4 Interventional

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

NCT05364385
View directory record Official record
Conditions
Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions
Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
Up to 18 Hours
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Jul 22, 2026, 2:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722
View directory record Official record
Conditions
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
Drug
Lead sponsor
enGene, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Terminated Phase 4 Interventional Results available

Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome

NCT02164734
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal intubation, Laryngeal mask airway, remifentanil
Device · Drug
Lead sponsor
Albany Medical College
Other
Eligibility
2 Hours to 48 Hours
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Not applicable Interventional

LISA in the Delivery Room for Extremely Preterm Infants

NCT04715373
View directory record Official record
Conditions
Extreme Prematurity, Respiratory Distress Syndrome
Interventions
LISA
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
5 Minutes to 20 Minutes
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Jul 22, 2026, 2:20 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Little Lungs Study

NCT06855043
View directory record Official record
Conditions
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Interventions
Calfactant, Budesonide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
7 Days to 14 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 2Phase 3 Interventional

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

NCT01203358
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Interventions
Exosurf, Survanta
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 6 Hours
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 1992
U.S. locations
13
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide

NCT00569530
View directory record Official record
Conditions
Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction), Bronchopulmonary Dysplasia
Interventions
Infasurf (ONY Inc.), Sham
Drug
Lead sponsor
Roberta Ballard
Other
Eligibility
7 Days to 14 Days
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Berkeley, California • Oakland, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 22, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional Results available

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

NCT00215540
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
Interventions
Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
3 Days to 10 Days
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Warrington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Not applicable Interventional

A Randomized Trial Evaluating EARLY Application of a Surfactant Dressing in Thermal Injury (EARLY)

NCT04880655
View directory record Official record
Conditions
Burns, Partial-thickness Burn
Interventions
WSD, Dressed with bacitracin and petrolatum gauze
Device
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

NCT03058666
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Aerosolized Calfactant, Solarys
Drug · Device
Lead sponsor
ONY
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Jul 22, 2026, 2:20 PM EDT
Recruiting Phase 4 Interventional

Non Inferiority Trial Investigating Surfactants Administered Via MIST

NCT06074380
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
MIST surfactant
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
Up to 48 Hours
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 22, 2026, 2:20 PM EDT
Active, not recruiting Phase 3 Interventional Results available

The Budesonide in Babies (BiB) Trial

NCT04545866
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
Interventions
budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Not applicable Interventional

A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants

NCT05094700
View directory record Official record
Conditions
Dermatitis, Atopic, Rosacea, Acne Vulgaris, Sensitive Skin
Interventions
Non-marketed Cosmetic Facial Cleanser
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Jul 22, 2026, 2:20 PM EDT
Not yet recruiting Not applicable Interventional

Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration

NCT07442669
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
Interventions
Lung ultrasound
Diagnostic Test
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
27 Weeks to 34 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 1Phase 2 Interventional

Delivery Room CPAP in Extremely Low Birth Weight Infants

NCT01223274
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia, Continuous Positive Airway Pressure
Interventions
CPAP/PEEP, Standard management practices
Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 10 Minutes
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial

NCT02907593
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD)
Interventions
Budesonide in Calfactant
Drug
Lead sponsor
Cynthia McEvoy
Other
Eligibility
3 Days to 14 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 22, 2026, 2:20 PM EDT
Available No phase listed Expanded access

Molgramostim Nebulizer Solution Expanded Access Program Protocol

NCT06546098
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim nebulizer solution
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
U.S. locations
9
States / cities
Los Angeles, California • Gainesville, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Completed No phase listed Observational

Surfactant Protein Genetic Variants in COVID-19 Infection

NCT04650191
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Identification of genetic variants
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Day to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Jul 22, 2026, 2:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiology of Surfactant Protein-B Deficiency

NCT00014859
View directory record Official record
Conditions
Lung Diseases, Respiratory Distress Syndrome, Newborn, Pulmonary Surfactant, Lung Diseases, Interstitial
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 1 Year
Enrollment
5,176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Jul 22, 2026, 2:20 PM EDT
Recruiting Not applicable Interventional

Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure

NCT07274527
View directory record Official record
Conditions
Neonatal Respiratory Distress Related Conditions, Meconium, Perinatal Morbidity, Neonatal Acidosis, Cord Blood, Neonatal Brain Injury, Maternal Morbidity, Mechanical Ventilation, CPAP, Surfactant, Perinatal Death, Amnioinfusion, NICU Admission
Interventions
Intrauterine pressure catheter, Standard obstetric care at discretion of delivery provider
Device · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 2:20 PM EDT